July 17, 2025 a 11:43 am
INCY: Fundamental Ratio Analysis - Incyte Corporation
Incyte Corporation presents a mixed outlook with strong drug offerings and promising clinical trials. However, investors should be cautious of the risks inherent in the biopharmaceutical industry, including regulatory challenges and market competition. Overall, the company has shown resilience with its focus on innovation and strategic partnerships.
Fundamental Rating
The company currently holds a B+ rating, reflecting above-average fundamentals. Its discounted cash flow and debt-to-equity ratios are strengths, although the price-to-earnings ratio is a weaker point.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 3 | |
| Return on Assets | 3 | |
| Debt to Equity | 4 | |
| Price to Earnings | 1 | |
| Price to Book | 2 |
Historical Rating
The historical scores indicate consistent performance in fundamental aspects, with no significant changes in the last assessment.
| Date | Overall Score | DCF | ROE | ROA | Debt to Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-07-17 | 3 | 5 | 3 | 3 | 4 | 1 | 2 |
| 2025-07-16 | 3 | 5 | 3 | 3 | 4 | 1 | 2 |
Analyst Price Targets
Analyst price targets suggest a stable potential for growth with consensus set at a median of $79.5. The targets range from a low of $67 to a high of $92.
| High | Low | Median | Consensus |
|---|---|---|---|
| $92 | $67 | $79.5 | $79.5 |
Analyst Sentiment
The stock enjoys a positive sentiment among analysts with a predominant recommendation to buy or hold.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 21 | |
| Hold | 20 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Incyte Corporation displays a robust portfolio of therapeutics, with a consistent fundamental performance that attracts a positive analyst sentiment. The company's innovative approach and strategic partnerships are promising, though potential regulatory and competitive risks remain. Overall, the stock is considered a stable buy with the potential for moderate growth.